Replies to post #197112 on Avid Bioservices Inc (CDMO)

[md1225]

The street want one of those three PRs imo. We have GREAT science PRs, actually the BEST science PRs in the biotech arena imo.

BUT we need one of those three to kick start the price movement.

Immunotherapy!!!!

Merck will get an upfront payment of $850 million from the U.S. drugmaker for sharing rights to develop its experimental immunotherapy drug with Pfizer. It is also eligible for up to $2 billion in payments based on the medicine's future success.

Merck's MSB0010718C is part of a class of drugs known as anti-PD-L1 therapies, which work by blocking a tumor's ability to evade the immune system's defense.

The exclusive nature of the deal means Pfizer and Merck cannot collaborate with any other drugmaker in the PD-LI or related PD-1 area, unless they jointly agree to do so.

Such immune-boosting medicines represent the hottest area of cancer research and are also a major focus for AstraZeneca, which has a rival anti-PD-L1 product in development called MEDI4736.